Journal article
Refine
Has Fulltext
- yes (650)
Year of publication
- 2020 (650) (remove)
Document Type
- Journal article (650) (remove)
Language
- English (613)
- German (35)
- French (1)
- Multiple languages (1)
Keywords
- boron (9)
- multiple myeloma (9)
- machine learning (8)
- COVID-19 (7)
- autophagy (6)
- biodiversity (6)
- cancer (6)
- depression (6)
- inflammation (6)
- toxicity (6)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (99)
- Medizinische Klinik und Poliklinik II (45)
- Institut für Anorganische Chemie (38)
- Neurologische Klinik und Poliklinik (32)
- Institut für Organische Chemie (29)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (26)
- Institut für Psychologie (24)
- Institut für Geographie und Geologie (23)
- Institut für Klinische Epidemiologie und Biometrie (22)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (22)
Sonstige beteiligte Institutionen
- Agricultural Center, BASF SE, 67117 Limburgerhof, Germany (1)
- Core Unit Systemmedizin (1)
- Institute of Organic Chemistry and Center for Molecular Biosciences Innsbruck, CMBI, Leopold-Franzens University Innsbruck, Austria (1)
- Interdisciplinary Center for Clinical Research (1)
- Mildred Scheel Early Career Center (1)
- Paul Scherrer Institut (1)
The process of viral integration into the host genome is an essential step of the HIV-1 life cycle. The viral integrase (IN) enzyme catalyzes integration. IN is an ideal therapeutic enzyme targeted by several drugs; raltegravir (RAL), elvitegravir (EVG), dolutegravir (DTG), and bictegravir (BIC) having been approved by the USA Food and Drug Administration (FDA). Due to high HIV-1 diversity, it is not well understood how specific naturally occurring polymorphisms (NOPs) in IN may affect the structure/function and binding affinity of integrase strand transfer inhibitors (INSTIs). We applied computational methods of molecular modelling and docking to analyze the effect of NOPs on the full-length IN structure and INSTI binding. We identified 13 NOPs within the Cameroonian-derived CRF02_AG IN sequences and further identified 17 NOPs within HIV-1C South African sequences. The NOPs in the IN structures did not show any differences in INSTI binding affinity. However, linear regression analysis revealed a positive correlation between the Ki and EC50 values for DTG and BIC as strong inhibitors of HIV-1 IN subtypes. All INSTIs are clinically effective against diverse HIV-1 strains from INSTI treatment-naïve populations. This study supports the use of second-generation INSTIs such as DTG and BIC as part of first-line combination antiretroviral therapy (cART) regimens, due to a stronger genetic barrier to the emergence of drug resistance.